Evidence map›Paper›PMID 40410562›Full record

ArticleInternational journal of hematology2025

Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.

Hiroaki Konishi, Takayoshi Tachibana, Shota Arai, Akihiko Izumi, Takaaki Takeda, Natsuki Hirose, Jun Nukui, Shuku Sato, Taisei Suzuki, Ryuji Ishii and 7 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hiroaki KonishiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Takayoshi TachibanaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan. tachibana.tak.kt@yokohama-cu.ac.jp.ORCID http://orcid.org/0000-0002-7780-4459
Shota AraiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Akihiko IzumiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Takaaki TakedaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Natsuki HiroseDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Jun NukuiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Shuku SatoDivision of Hematology, Shonan Kamakura General Hospital, Kamakura, Japan.
Taisei SuzukiDepartment of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
Ryuji IshiiDepartment of Hematology, Japan Community Health Care Organization Sagamino Hospital, Sagamihara, Japan.
Etsuko YamazakiDepartment of Hematology, Yokohama Rosai Hospital, Yokohama, Japan.
Manabu MatsunawaDivision of Hematology, Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Junichi MukaeDepartment of Hematology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan.
Atsushi TakahataDepartment of Hematology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Takahiro SuzukiDepartment of Hematology, Kitasato University School of Medicine, Sagamihara, Japan.
Hideaki NakajimaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to compare the efficacy and safety of preemptive and maintenance therapies as post-transplant therapy for acute myeloid leukemia (AML). Patients with AML who underwent allogeneic stem cell transplantation and received post-transplant therapy were eligible. Preemptive therapy was initiated if elevated Wilms' tumor-1 mRNA was detected in the peripheral blood. Twenty-nine patients received either preemptive (n = 12) or maintenance therapy (n = 17). The median age was 56 years (range, 18-70). The median time from transplantation to intervention was 77 days (range, 43-203) for maintenance and 346 days (range, 104-1027) for preemptive therapy. Maintenance therapy consisted of azacitidine (AZA) monotherapy in six patients, venetoclax (VEN) + AZA in five, and VEN + cytarabine (AraC) in six. Preemptive therapy consisted of AZA monotherapy in two patients, VEN + AZA in nine, and VEN + AraC in one. One-year overall survival from intervention was 92% for maintenance and 73% for preemptive therapy (P = 0.28), and 1-year event-free survival was 83% and 66%, respectively (P = 0.29). No serious adverse events or treatment-related mortality were observed in either group. Both therapies were safe and effective in preventing disease relapse. A prospective study comparing these two groups is warranted.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMaintenance ChemotherapyAdolescentAdultAgedAllograftsAzacitidineBridged Bicyclo Compounds, HeterocyclicCytarabineFemaleHumansMaleMiddle AgedSulfonamidesAzacitidineBridged Bicyclo Compounds, HeterocyclicCytarabineSulfonamidesvenetoclaxAcute myeloid leukemiaAllogeneic stem cell transplantationMaintenance therapyPreemptive therapyWT1

Identifiers

PMID40410562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.